Core Viewpoint - The Hong Kong medical sector is experiencing a strong upward trend, with the CSI Hong Kong Stock Connect Medical Theme Index showing significant gains, and the Hong Kong medical ETF demonstrating high liquidity and performance [1][5]. Group 1: Market Performance - As of September 5, 2025, the CSI Hong Kong Stock Connect Medical Theme Index (932069) has seen strong increases, with constituent stocks such as Zhaoyan Pharmaceutical, Kanglong Chemical, and Jingtai Holdings rising [1]. - The Hong Kong medical ETF (159366) has increased nearly 2%, with a 30% rise over the past 60 days and an average daily trading volume of 338 million [1]. - The top ten weighted stocks in the CSI Hong Kong Stock Connect Medical Theme Index account for 61.05% of the index, indicating a concentrated performance among leading companies [5]. Group 2: Sector Insights - The CRO/CMO segment is identified as the fastest-growing sub-sector, with a year-on-year growth rate of 12.6%, indicating a recovery from previous challenges [3]. - Chemical pharmaceuticals and CRO/CMO sectors have shown impressive non-GAAP net profit growth rates of 21.1% and 20.9% respectively, significantly outperforming the industry average decline of 13.3% [4]. - The current medical fund holdings are at a low level of 6.9%, suggesting potential for growth in investment allocations within the sector [4]. Group 3: Investment Sentiment - The market sentiment is bolstered by expectations of interest rate cuts from the Federal Reserve, which is favorable for interest-sensitive sectors [3]. - The industry is currently at a historical low in terms of valuation, with a price-to-earnings ratio (TTM) of 31 times, indicating potential for upward movement as innovation drives growth [4].

Group 1 - The core index of the CSI 1000 Healthcare Index closed at 14247.06 points, with a one-month increase of 7.51%, a three-month increase of 25.91%, and a year-to-date increase of 32.65% [1] - The CSI 1000 Index series selects liquid and representative securities from each industry to form ten industry indices, providing diversified investment targets for investors [1] - The top ten holdings in the CSI 1000 Healthcare Index include: Borui Pharmaceutical (3.76%), Tonghua Golden Horse (2.77%), Zai Jian Pharmaceutical (2.39%), Furuide Co. (1.96%), Zhongsheng Pharmaceutical (1.83%), Rongchang Bio (1.69%), Zhaoyan New Drug (1.69%), Zuoli Pharmaceutical (1.62%), Anke Bio (1.61%), and Yipin Hong (1.46%) [1] Group 2 - The market share of the CSI 1000 Healthcare Index holdings is 54.86% from the Shanghai Stock Exchange and 45.14% from the Shenzhen Stock Exchange [1] - The industry composition of the CSI 1000 Healthcare Index includes: Chemical drugs (34.72%), Medical devices (20.46%), Traditional Chinese medicine (16.77%), Biological drugs (14.77%), Medical commerce and services (7.27%), and Pharmaceutical and biotechnology services (6.01%) [2] - The index sample is adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December, and can be adjusted temporarily under special circumstances [2]

Group 1 - The core viewpoint of the article highlights the significant performance of the China Securities Hong Kong 100 Healthcare Index, which has seen a remarkable increase of 21.00% in the past month, 52.68% in the past three months, and 95.84% year-to-date [1] - The index is categorized based on the China Securities industry classification standards, with a base date of December 31, 2004, and a base point of 1000.0 [1] - The index is fully composed of securities listed on the Hong Kong Stock Exchange, with the chemical drugs sector accounting for 54.75%, biopharmaceuticals for 18.73%, pharmaceutical and biotechnology services for 14.45%, and medical commerce and services for 12.07% [1] Group 2 - The index samples are adjusted biannually, specifically on the next trading day following the second Friday of June and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with provisions for temporary adjustments under special circumstances [2] - Adjustments to the index samples occur in response to changes in the parent index, special events affecting industry classification, or the delisting of sample companies [2]

资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。特殊情况下将对指数进行临时调整。当对应的母指数调整样本时， 行业指数样本将相应调整。当样本公司有特殊事件发生，导致其行业归属发生变更时，将对指数进行相 应调整。当样本退市时，将其从指数样本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照 计算与维护细则处理。 本文源自：金融界 数据统计显示，中证香港100医药卫生指数近一个月上涨20.84%，近三个月上涨44.95%，年至今上涨 89.44%。 据了解，中证香港100行业指数系列将中证香港100指数样本按中证行业分类标准进行分类，再以各自行 业全部证券作为对应行业指数的样本。该指数以2004年12月31日为基日，以1000.0点为基点。 从中证香港100医药卫生指数持仓的市场板块来看，香港证券交易所占比100.00%。 从中证香港100医药卫生指数持仓样本的行业来看，化学药占比55.11%、生物药品占比18.62%、制药与 生物科技服务占比 ...

金融界8月6日消息，上证指数低开高走，中证香港100医药卫生指数 (H100医药，L11185)报1134.87点。 数据统计显示，中证香港100医药卫生指数近一个月上涨22.21%，近三个月上涨41.09%，年至今上涨 96.31%。 据了解，中证香港100行业指数系列将中证香港100指数样本按中证行业分类标准进行分类，再以各自行 业全部证券作为对应行业指数的样本。该指数以2004年12月31日为基日，以1000.0点为基点。 从中证香港100医药卫生指数持仓的市场板块来看，香港证券交易所占比100.00%。 从中证香港100医药卫生指数持仓样本的行业来看，化学药占比54.47%、生物药品占比19.42%、制药与 生物科技服务占比14.91%、医疗商业与服务占比11.20%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。特殊情况下将对指数进行临时调整。当对应的母指数调整样本时， 行业指数样本将相应调整。当样本公司有特殊事件发生，导致其行 ...

Core Viewpoint - The China Securities Index for Hong Kong Stock Connect Medical Theme has shown significant growth, with a year-to-date increase of 58.75% [1] Group 1: Index Performance - The index rose by 2.58% to 1088.62 points, with a trading volume of 19.47 billion [1] - Over the past month, the index has increased by 16.48%, and over the last three months, it has risen by 31.51% [1] Group 2: Index Composition - The index comprises 50 listed companies involved in medical devices, medical services, pharmaceuticals, and biotechnology [1] - The top ten weighted companies in the index include WuXi Biologics (15.03%), JD Health (10.75%), and WuXi AppTec (6.59%) [1] Group 3: Sector Allocation - The index's holdings are entirely from the Hong Kong Stock Exchange [2] - The sector breakdown of the index includes: Pharmaceuticals and Biotechnology Services (33.30%), Medical Services (32.85%), Medical Devices (12.81%), Chemical Drugs (12.34%), and Biological Drugs (8.70%) [2] Group 4: Index Adjustment Mechanism - The index samples are adjusted biannually, with changes implemented on the next trading day after the second Friday of June and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with special adjustments made under certain circumstances [2]

Group 1 - The core viewpoint of the news is that the China Securities Hong Kong 100 Pharmaceutical and Health Index has shown significant growth, with a year-to-date increase of 90.32% [1] - The index has risen by 18.48% in the past month and 36.79% in the last three months, indicating strong performance in the pharmaceutical sector [1] - The index is composed entirely of securities listed on the Hong Kong Stock Exchange, with a base date of December 31, 2004, and a base point of 1000.0 [1] Group 2 - The index sample is adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2] - Weight factors are generally fixed until the next scheduled adjustment, but can be temporarily modified under special circumstances [2] - Adjustments to the index sample occur in response to events such as delistings, mergers, or changes in industry classification [2]

Core Insights - The CSI 1000 Healthcare Index has shown significant growth, with a 13.89% increase over the past month, 24.30% over the last three months, and 27.10% year-to-date [1] Group 1: Index Performance - The CSI 1000 Healthcare Index is currently at 13651.50 points [1] - The index is designed to provide a diversified investment option by selecting liquid and representative securities from each industry [1] Group 2: Index Holdings - The top ten weighted stocks in the CSI 1000 Healthcare Index include: - Borui Pharmaceutical (3.51%) - Tonghua Golden Horse (2.65%) - Zai Lab (2.51%) - Zhongsheng Pharmaceutical (1.75%) - Zhaoyan New Drug (1.70%) - Anke Biotechnology (1.66%) - Yipinhong (1.63%) - Zuoli Pharmaceutical (1.59%) - Furuide (1.39%) - Dongcheng Pharmaceutical (1.33%) [1] - The index's market distribution shows that the Shanghai Stock Exchange accounts for 55.62%, while the Shenzhen Stock Exchange accounts for 44.38% [1] Group 3: Industry Composition - The industry composition of the CSI 1000 Healthcare Index is as follows: - Chemical drugs: 36.28% - Medical devices: 19.30% - Traditional Chinese medicine: 17.00% - Biological drugs: 14.30% - Medical commerce and services: 7.16% - Pharmaceutical and biotechnology services: 5.94% [2] Group 4: Sample Adjustment - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December [2] - In special circumstances, the index may undergo temporary adjustments [2] - When a sample company is delisted, it will be removed from the index, and any mergers, acquisitions, or splits will be handled according to maintenance guidelines [2]

金融界8月4日消息，上证指数低开高走，中证香港100医药卫生指数 (H100医药，L11185)报1091.30点。 从中证香港100医药卫生指数持仓样本的行业来看，化学药占比54.55%、生物药品占比19.02%、制药与 生物科技服务占比15.26%、医疗商业与服务占比11.18%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。特殊情况下将对指数进行临时调整。当对应的母指数调整样本时， 行业指数样本将相应调整。当样本公司有特殊事件发生，导致其行业归属发生变更时，将对指数进行相 应调整。当样本退市时，将其从指数样本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照 计算与维护细则处理。 本文源自：金融界 作者：行情君 数据统计显示，中证香港100医药卫生指数近一个月上涨20.90%，近三个月上涨36.74%，年至今上涨 88.77%。 据了解，中证香港100行业指数系列将中证香港100指数样本按中证行业分类标准进行分类，再以各自行 业 ...

从中证沪港深500医药卫生指数持仓的市场板块来看，香港证券交易所占比37.87%、上海证券交易所占 比33.61%、深圳证券交易所占比28.52%。 从中证沪港深500医药卫生指数持仓样本的行业来看，化学药占比36.20%、制药与生物科技服务占比 18.33%、生物药品占比18.14%、医疗器械占比11.07%、中药占比8.56%、医疗商业与服务占比7.70%。 资料显示，该指数系列样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五 的下一交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一 个定期调整日前，权重因子一般固定不变。特殊情况下将对该指数系列样本进行临时调整。当样本退市 时，将其从指数样本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照计算与维护细则处 理。当中证沪港深500指数、中证沪港深互联互通中小综合指数和中证沪港深互联互通综合指数样本发 生变动时，将进行相应调整。 金融界8月1日消息，上证指数下跌0.37%，中证沪港深500医药卫生指数 (沪港深500医药，H30463)下跌 1.74%，报8507.96点，成交额405.94亿元 ...